21:21 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis. Vertex has rights to VX-210 from BioAxone...
15:19 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology; ophthalmic disease

INDICATION: Parkinson’s disease (PD); neurology; blindness Fruit fly studies suggest inhibiting ITPR, VDAC1, MCU, MIRO1 and/or MIRO2 could help treat PD, other neurodegenerative diseases and blindness. In a Drosophila model of PD, knockdown of ITPR...
20:56 , Oct 19, 2017 |  BC Innovations  |  Translation in Brief

Go/No-Go decider

A Wistar Institute team has shown syntaphilin (SNPH) , known as a mitochondrial regulator in neurons, acts in cancer cells to mediate the decision of whether to proliferate or metastasize. While modulating the protein is...
23:03 , Jun 29, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: June 2017

New Therapeutic Targets and Biomarkers: June 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during June 2017. Therapeutic targets are defined as any protein, gene or other...
20:22 , Jun 13, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on ARHGAP15 and COLQ could help predict the risk of diverticular disease, and a SNP on FAM155A could help predict the risk of diverticulitis. Genome-wide association studies in 5,426 diverticular disease patients,...
03:26 , Jun 3, 2017 |  BioCentury  |  Product Development

Leading with lung

Lung cancer squeezed past breast cancer as the top indication at the American Society of Clinical Oncology meeting this year as targeted therapies duke it out within genetically defined subgroups, while immunotherapies seek their best...
07:00 , Jul 23, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Claudin 18 (CLDN18)-Rho GTPase activating protein 26 (ARHGAP26) fusion gene as a risk marker for gastric cancer

Biomarkers ARHGAP26 Claudin 18 CLDN18 Rho GTPase activating protein 26 (ARHGAP26)...
08:00 , Feb 13, 2014 |  BC Innovations  |  Tools & Techniques

Micromanaging the microenvironment

A Massachusetts team has designed an in vivo shRNA screen to discover immunosuppressive tumor targets that can be blocked to improve the efficacy of T cell immunotherapies. 1 The screening system shows that current checkpoint...
07:00 , May 21, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 receptor (RTN4R; NgR) Studies in mice suggest that a soluble peptide fragment of NgR (sNgR)...
07:00 , May 11, 2009 |  BC Week In Review  |  Company News

Alseres, BioAxone deal

Alseres (formerly Boston Life Sciences Inc. ) is no longer required to pay milestones to BioAxone under a 2006 deal that granted Alseres exclusive, worldwide rights to BioAxone's Cethrin . In return, Alseres has an...